Literature DB >> 15476279

The prion protein in human neuromuscular diseases.

Gábor G Kovács1, Ognian Kalev, Ellen Gelpi, Christine Haberler, Julia Wanschitz, Michaela Strohschneider, Mária J Molnár, Lajos László, Herbert Budka.   

Abstract

The basis of human prion diseases affecting the nervous system is accumulation of a disease-associated conformer (PrPSc) of the normal cellular prion protein (PrPC). Earlier studies demonstrated increased expression of PrPC in inclusion body myositis (IBM), dermato-, and polymyositis, as well as neurogenic muscle atrophy. To define the spectrum and reliability of PrPC immunoreactivity, its expression was examined systematically in a series of pathologically characterized muscular disorders by means of immunohistochemistry, confocal laser microscopy, and immunogold electron microscopy. Anti-PrPC immunolabelling of rimmed vacuoles was observed in IBM, inclusions of myofibrillary myopathy, targets, regenerating, and atrophic fibres, mononuclear cells, in addition to ragged red fibres in mitochondrial myopathies, and focal sarcolemmal immunostaining in non-diseased controls. Quantitative analysis demonstrated that, in neurogenic muscle lesions, anti-PrPC staining detects a significantly broader spectrum of fibres than anti-vimentin or anti-NCAM. In dystrophic muscle, PrPC expression was mainly restricted to regenerating fibres. In IBM, PrPC expression was not confined to rimmed vacuoles or vacuolated fibres and only a small percentage (7.1%) of rimmed vacuoles were PrPC positive. Ultrastructurally, PrPC was observed in the cytoplasm of lymphocytes, in the myofibrillar network of targets, and in rimmed vacuoles. Knowledge of disease circumstances with altered expression of PrPC is important in the setting of a potentially increased chance for extraneural PrPC-PrPSc conversion. In addition, our observations suggest that PrPC may have a general stress-response effect in various neuromuscular disorders. Copyright (c) 2004 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476279     DOI: 10.1002/path.1633

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Prion infection of muscle cells in vitro.

Authors:  Wendy M Dlakic; Eric Grigg; Richard A Bessen
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

2.  Detection of PrPSc in lung and mammary gland is favored by the presence of Visna/maedi virus lesions in naturally coinfected sheep.

Authors:  Eider Salazar; Eva Monleón; Rosa Bolea; Cristina Acín; Marta Pérez; Neila Alvarez; Iratxe Leginagoikoa; Ramón Juste; Esmeralda Minguijón; Ramsés Reina; Idoia Glaria; Eduardo Berriatua; Damián de Andrés; Juan José Badiola; Beatriz Amorena; Lluís Luján
Journal:  Vet Res       Date:  2010-04-29       Impact factor: 3.683

3.  Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity.

Authors:  Jinze Qian; Jingmin Yan; Fengxia Ge; Beiru Zhang; Xiaoying Fu; Hiroshi Tomozawa; Jinko Sawashita; Masayuki Mori; Keiichi Higuchi
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

Review 4.  Prion diseases: from protein to cell pathology.

Authors:  Gabor G Kovacs; Herbert Budka
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

Review 5.  Molecular pathology of human prion diseases.

Authors:  Gabor G Kovacs; Herbert Budka
Journal:  Int J Mol Sci       Date:  2009-03-09       Impact factor: 5.923

6.  Myositis facilitates preclinical accumulation of pathological prion protein in muscle.

Authors:  Melanie Neumann; Susanne Krasemann; Katharina Schröck; Karin Steinbach; Markus Glatzel
Journal:  Acta Neuropathol Commun       Date:  2013-12-03       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.